Scott &White Memorial Hospital provides comprehensive, high quality health care for a 38 county area in Central Texas. Since the early 1900s, Scott &White has demonstrated leadership in providing innovative cancer care emphasized by medical education and research. Continuing with this tradition of quality care for the community, Scott &White seeks to continue its funding for the Community Clinical Oncology Program (CCOP) to support these objectives. The mission of the Scott &White Cancer Institute is "to provide the most comprehensive, highest quality cancer care, focusing on the prevention and treatment of cancer, enhanced by the application of scientific discoveries to ultimately improve the care of those living with cancer at Scott &White and throughout the world." Funding from the NCI since 1997 for our CCOP has enabled the Cancer Institute to evolve into a recognized leader in clinical cancer research and treatment for our service area. The proposed CCOP consists of the Scott &White component and Southwest Regional Cancer Center affiliate. The component and affiliate will work together in promoting innovative cooperative group studies in the community and contributing to quality research through refinement of processes to identify patients for protocol enrollment. The objectives for the CCOP will be to further support the commitment to delivering research options to the community that include cancer control, prevention, and treatment studies. The CCOP will continue to build on the existing strategies to recruit minority participants onto NCI-sponsored protocols by establishing relationships and by providing access to services in underserved areas. The disease-specific teams were developed to expedite patient discussion and treatment plan decisions, will continue to improve processes with a patient-centered approach to treatment. Community-based involvement will be strengthened by increasing participation in cancer-related organizations that support the goal of eradicating life-threatening cancers through education, research, and providing access for underserved areas. A consistent growth in the Central Texas area, increased health plan participation and the expansion of outreach clinics has placed an increasing demand for cancer services at Scott and White.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scott and White Memorial Hospital
United States
Zip Code
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13

Showing the most recent 10 out of 88 publications